Join us for this exciting conversation with Chris Whelan of Johnson & Johnson about muli-omics. He does a phenomenal job of explaining the basics, shines a light on some of the challenges of the field, all while staying conveying the hope of what this could all mean in terms of understanding and treating disease biology. Don't miss out - give our first episode a listen and subscribe for future episodes. Share with any colleagues or friends who might be interested. Experience the Speaking of Mol Bio podcast in its extended video format for a more immersive journey, while also ensuring accessibility with downloadable transcripts for each episode. Watch now at www.thermofisher.com/podcast-video
In this episode, we talk with Chris Whelan about the data behind science. Chris is the Director of Neuroscience, Data Science & Digital Health for Research and Development at The Janssen Pharmaceutical Companies of Johnson & Johnson, as well as the Chair of the UK Biobank Pharma Proteomics project. He connects the dots between genomics and proteomics and clarifies how omics can be used to understand disease biology to inform drug development to treat disease. The conversation touches on the challenges of defining and collecting a comprehensive biomarker panel, and he also delves into the role of data science and the importance of having people that understand biology being involved in data science applications that affect human health.
If you enjoy this great conversation with a leader in his field we hope you’ll subscribe to the series to get future episodes as they drop.
Visit https://thermofisher.com/molbioschool to access molecular biology resources and educational content.
Experience the Speaking of Mol Bio podcast in its extended video format for a more immersive journey, while also ensuring accessibility with downloadable transcripts for each episode.
Watch now at thermofisher.com/podcast-video